LON:AMYT Amryt Pharma (AMYT) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Amryt Pharma Stock (LON:AMYT) 30 days 90 days 365 days Advanced Chart Get Amryt Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume90,726 shsAverage Volume469,552 shsMarket Capitalization£457.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland. Read More Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Stock News HeadlinesAmryt Pharma plc (AMYT)August 21, 2024 | finance.yahoo.comAmryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi FarmaceuticiMarch 22, 2023 | finance.yahoo.comUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.August 16 at 2:00 AM | Stansberry Research (Ad)Chiesi Farmaceutici S.p.A. to acquire Amryt PharmaJanuary 16, 2023 | msn.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amryt Pharma Plc BuyoutJanuary 10, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBOJanuary 9, 2023 | benzinga.comAMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to ShareholdersJanuary 9, 2023 | technews.tmcnet.comItaly's Chiesi Farmaceutici to buy Amryt Pharma in a $1.48 billion dealJanuary 8, 2023 | news.yahoo.comSee More Headlines AMYT Stock Analysis - Frequently Asked Questions How do I buy shares of Amryt Pharma? Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include The Parkmead Group (PMG), Providence Resources (PVR), Ryanair (RYA), AIB Group (AIBG), Atalaya Mining (ATYM), Bank of Ireland Group (BIRG) and C&C Group (CCR). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolLON:AMYT Previous SymbolLON:FAST CIKN/A Webwww.amrytpharma.com Phone+44-20-34155730FaxN/AEmployees290Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio66.05 Current Ratio1.80 Quick Ratio1.14 Sales & Book Value Annual Sales£210.24 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.68 Book ValueGBX 96.60 per share Price / BookN/AMiscellaneous Outstanding Shares319,657,000Free FloatN/AMarket Cap£457.11 million OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:AMYT) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amryt Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.